Denali Therapeutics Inc. (DNLI) Financials
DNLI Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.2 billion | 123.0 million |
| 2023-09-30 | 1.2 billion | 118.4 million |
| 2023-06-30 | 1.3 billion | 118.9 million |
| 2023-03-31 | 1.4 billion | 442.6 million |
DNLI Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -100.9 million | 26.0 million |
| 2023-09-30 | -89.4 million | 27.5 million |
| 2023-06-30 | -119.0 million | 26.6 million |
| 2023-03-31 | -61.6 million | 28.1 million |
DNLI Net Income
No data available :(
DNLI Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 1.0 billion | - | 52.2 million |
| 2023-09-30 | 1.1 billion | - | 53.9 million |
| 2023-06-30 | 1.2 billion | - | 55.5 million |
| 2023-03-31 | 1.3 billion | - | 57.1 million |
DNLI Shares Outstanding
DNLI Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 2.2 million | 107.8 million | 24.8 million | 2.2 million |
| 2023-09-30 | 2.1 million | 89.7 million | 25.3 million | - |
| 2023-06-30 | 5.9 million | 97.5 million | 26.1 million | - |
| 2023-03-31 | 2.8 million | 128.8 million | 27.1 million | - |
DNLI Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | - | 2.2 million |
| 2023-09-30 | 1.3 million | 2.2 million |
| 2023-06-30 | 294.1 million | 1.4 million |
| 2023-03-31 | 35.1 million | 9.2 million |
DNLI
Price: $18.04
52 week price:
Earnings Per Share: -0.94 USD
P/E Ratio: -19.20
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 517900
Market Capitalization: 2.9 billion